HIV-1 RT mutations in patients after 24 weeks of tenofovir disoproxil fumarate (formerly PMPA prodrug) therapy

被引：0
|
作者：
Miller, MD [1 ]
Margot, NA [1 ]
Mills, R [1 ]
McGowan, I [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL RESEARCH | 2000年 / 46卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
8
引用
收藏
页码：A37 / A37
页数：1
相关论文
共 50 条
  • [1] The impact of Tenofovir disoproxil fumarate on renal function among Japanese patients with HIV-1 infection
    Nishijima, Takeshi
    Mizushima, Daisuke
    Aoki, Takahiro
    Watanabe, Koji
    Honda, Haruhito
    Yazaki, Hirohisa
    Tanuma, Junko
    Tsukada, Kunihisa
    Honda, Miwako
    Gatanaga, Hiroyuki
    Teruya, Katsuji
    Kikuchi, Yoshimi
    Oka, Shinichi
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (08) : 327 - 327
  • [2] Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
    Kabbaral, Wissam K.
    Ramadan, Wijdan H.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2015, 8 (05) : 409 - 417
  • [3] The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1
    McColl, DJ
    Miller, MD
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) : 219 - 223
  • [4] Synthesis and characterization of tenofovir disoproxil fumarate loaded nanoparticles for HIV-1 treatment
    Obisesan, Oluwafemi Samuel
    Tshweu, Lesego L.
    Chauke, Sipho
    Malatji, Kanyane Bridgett
    Ramalapa, Bathabile
    Alexandre, Kabamba B.
    Mufhandu, Hazel Tumelo
    NANO SELECT, 2024, 5 (06):
  • [5] Emtricitabine/Tenofovir Disoproxil Fumarate In Combination with a Protease Inhibitor in HIV-1 Infection
    Perry, Caroline M.
    DRUGS, 2009, 69 (07) : 843 - 857
  • [6] SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS
    Manns, M.
    Jeffers, L.
    Dalekos, G.
    Berg, T.
    Trepo, C.
    Roberts, S.
    Prieto, M.
    Rizzetto, M.
    Marcellin, P.
    Heathcote, E. J.
    Sorbel, J.
    Anderson, J.
    Mondou, E.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S335 - S336
  • [7] Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients
    Manns, Michael P.
    Jeffers, Lennox
    Delakos, Georgios N.
    Berg, Thomas
    Trepo, Christian
    Roberts, Stuart K.
    Prieto, Martin
    Rizzetto, Mario
    Marcellin, Patrick
    Heathcote, Jenny
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2009, 136 (05) : A799 - A799
  • [8] Tenofovir disoproxil fumarate - The first nucleotide reverse transcriptase inhibitor for treatment of patients with HIV-1 infection
    Coleman, C
    Ross, J
    Reddy, P
    FORMULARY, 2002, 37 (01) : 15 - +
  • [9] The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
    Wang, Huilian
    Lu, Xi
    Yang, Xudong
    Xu, Nan
    MEDICINE, 2016, 95 (41)
  • [10] Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate
    McColl, DJ
    Margot, NA
    Wulfsohn, M
    Coakley, DF
    Cheng, AK
    Miller, MD
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (03) : 1340 - 1350
12345